Welcome to our dedicated page for Whitehawk Therapeutics SEC filings (Ticker: WHWK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Whitehawk Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Whitehawk Therapeutics's regulatory disclosures and financial reporting.
Coastlands-related parties report beneficial ownership of 2,819,215 shares of Whitehawk Therapeutics common stock, representing 5.98% of the outstanding shares based on 47,128,362 shares cited as of August 4, 2025. The holdings are reported across Coastlands Capital LP, Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC and Matthew D. Perry. Voting and dispositive power is reported as shared for most entities, with Coastlands Capital GP LLC showing sole voting and dispositive power in one cover-sheet entry, while other reporting persons indicate shared power. The filing states the securities were acquired and are held in the ordinary course of business and are not intended to change or influence control of the issuer.
In its first quarter post-divestiture, Whitehawk Therapeutics (WHWK) filed a Q2 2025 10-Q showing a markedly stronger balance sheet and a shift to pre-clinical R&D.
Liquidity: Cash, cash equivalents and short-term investments rose to $177.2 M from $47.2 M at YE-24, funded by the $102.4 M sale of FYARRO (closed 25 Mar 25) and a $100 M PIPE (21.6 M shares & 20.1 M pre-funded warrants at $2.40).
Operations: With FYARRO gone, Q2 revenue fell to $0 (vs $6.2 M). R&D expense jumped to $48.8 M (Q2 24: $13.1 M) after paying the remaining $38 M WuXi license fee for three antibody-drug conjugate (ADC) programs. SG&A declined 25 % YoY to $5.9 M. Net loss widened to $52.6 M (-$0.76/sh).
Six-month view: An $87.4 M gain on the FYARRO sale produced $20.4 M net income for 1H 25, yet operating cash burn reached $64.8 M.
- Total assets: $180.8 M; liabilities: $8.8 M; no debt.
- Equity climbed to $172.1 M and shares outstanding to 47.1 M (8 Aug 25).
- Outstanding dilution: 22.1 M pre-funded warrants & 7.6 M options.
Outlook: Management believes current cash funds ≥12 months of accelerated ADC development; future value creation now hinges on advancing these pre-clinical candidates into the clinic.
FAQ
What is the current stock price of Whitehawk Therapeutics (WHWK)?
What is the market cap of Whitehawk Therapeutics (WHWK)?
